title: Effect of hormone replacement therapy in women on ocular refractive status and aberrations.
abstract: OBJECTIVE
  To evaluate the effects of hormone replacement therapy (HRT) on refractive status, corneal topography, and aberrations of the eye in postmenopausal women.
  
  
  METHODS
  Thirty-six healthy postmenopausal women (72 eyes) were included in the study. All patients received HRT that consisted of 0.625 mg/day conjugated estrogen and 5 mg/day medroxyprogesterone acetate in a continuous combined regimen. Schirmer II test and tear film break-up time (BUT) were performed on all patients at the time of enrollment and 6 months after initiation of HRT. Refractive status, corneal topography, and wavefront aberrations were evaluated with the NIDEK Optical Path Difference-Scan before and 6 months after HRT was initiated.
  
  
  RESULTS
  Mean patient age was 50.8 +/- 2.6 years (range: 47 to 57 years). The mean duration of menopause was 2.7 +/- 0.8 years (range: 1.4 to 3.5 years). The Schirmer II test and tear film BUT measurements were significantly lower after HRT (P < .05). Before HRT, the mean spherical equivalent refraction was -0.19 +/- 1.79 diopters (D) (range: -4.38 to +3.00 D). After HRT, the mean spherical equivalent refraction was -0.22 +/- 1.81 D (range: -4.63 to +/- 2.63 D). No significant differences were noted between refractive status, corneal topography, and wavefront aberrations of eyes of patients before and 6 months after HRT (P > .05).
  
  
  CONCLUSIONS
  Hormone replacement therapy in postmenopausal women does not significantly affect refractive status, corneal topography, and wavefront aberrations of the eye at 6-month follow-up.
authors.affiliation: Department of Ophthalmology, Gülhane Military Medical School, Ankara, Turkey. erdemuzeyir@hotmail.com
authors.forename: Uzeyir
authors.initials: U
authors.lastname: Erdem
authors.forename: Orkun
authors.initials: O
authors.lastname: Muftuoglu
authors.forename: Umit
authors.initials: U
authors.lastname: Goktolga
authors.forename: Selim
authors.initials: S
authors.lastname: Dagli
mesh_terms: D003315:Cornea / Q000503:physiopathology; D019781:Corneal Topography; D004359:Drug Therapy, Combination; D015914:Estrogen Replacement Therapy; D004966:Estrogens, Conjugated (USP) / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D017258:Medroxyprogesterone Acetate / Q000627:therapeutic use*; D008875:Middle Aged; D012029:Refraction, Ocular / Q000502:physiology*; D012030:Refractive Errors / Q000503:physiopathology*
chemical_list: D004966:Estrogens, Conjugated (USP); D017258:Medroxyprogesterone Acetate